Table 4.
Characteristics of included subjects at first study visit.
| Study 1 (n = 202) | Study 2 (n = 100) | Study 3 (n = 162) | Study 4 (n = 149) | Total (n = 613) | p-Value | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age | <0.0001 | |||||||||||
| Mean (SD) | 55.9 | (11.6) | 51.3 | (8.7) | 56.6 | (8.6) | 52.1 | (10.1) | 54.4 | (10.2) | ||
| [min, max] | [26, 88] | [28, 76] | [36, 78] | [26, 75] | [26, 88] | |||||||
| Months since treatment | <0.0001 | |||||||||||
| Mean (SD) | −5.3 | (3.9) | 12.1 | (8.0) | 45.0 | (28.3) | −2.3 | (4.7) | 11.6 | (25.9) | ||
| [min, max] | [−21.4, 0.0] | [2.1, 34.0] | [11.4, 131.3] | [−32.9, 4.6] | [−32.9, 131.3] | |||||||
| Energy/Fatigue scale, RAND36 * | <0.0001 | |||||||||||
| Mean (SD) | 53.3 | (23.4) | 44.4 | (20.9) | 61.0 | (19.0) | 50.7 | (19.9) | 53.3 | (21.7) | ||
| [min, max] | [0, 100] | [5, 90] | [0, 95] | [0, 100] | [0, 100] | |||||||
| BMI | 0.20 | |||||||||||
| Mean (SD) | 28.9 | (7.3) | 27.6 | (6.0) | 27.7 | (5.8) | 28.6 | (5.7) | 28.3 | (6.4) | ||
| [min, max] | [15.8, 58.7] | [16.2, 43.9] | [18.7, 45.5] | [16.8, 49.6] | [15.8, 58.7] | |||||||
| Race | 0.03 ^ | |||||||||||
| White | 79% | (160) | 88% | (88) | 92% | (149) | 86% | (128) | 86% | (525) | ||
| Black | 15% | (30) | 10% | (10) | 6% | (10) | 9% | (13) | 10% | (63) | ||
| Asian | 3% | (7) | 2% | (2) | 0.6% | (1) | 2% | (3) | 2% | (13) | ||
| Native American | 2% | (4) | 0% | (0) | 0% | (0) | 1% | (1) | 1% | (5) | ||
| Other | 0% | (1) | 0% | (0) | 0% | (0) | 0% | (0) | 0% | (1) | ||
| Mixed | 0% | (0) | 0% | (0) | 1% | (2) | 3% | (4) | 1% | (6) | ||
| Education | <0.0001 | |||||||||||
| HS or less | 29% | (58) | 7% | (7) | 11% | (18) | 15% | (22) | 17% | (105) | ||
| Some college | 21% | (43) | 22% | (22) | 17% | (28) | 25% | (37) | 21% | (130) | ||
| College grad | 24% | (48) | 33% | (33) | 37% | (60) | 31% | (46) | 31% | (187) | ||
| Grad/prof training | 26% | (53) | 38% | (38) | 35% | (56) | 30% | (44) | 31% | (191) | ||
| Cancer Stage | <0.0001 | |||||||||||
| Stage 0 | 18% | (37) | 9% | (9) | 0% | (0) | 0% | (0) | 8% | (46) | ||
| Stage 1 | 45% | (90) | 43% | (43) | 47% | (76) | 50% | (74) | 46% | (283) | ||
| Stage 2 | 27% | (55) | 38% | (38) | 48% | (77) | 47% | (70) | 39% | (240) | ||
| Stage 3 | 9% | (19) | 10% | (10) | 6% | (9) | 3% | (5) | 7% | (43) | ||
| Missing | -- | (1) | -- | (0) | -- | (0) | -- | (0) | -- | (1) | ||
| Cancer Treatment | <0.0001 | |||||||||||
| Surgery | 30% | (61) | 13% | (13) | 12% | (19) | 31% | (46) | 23% | (139) | ||
| Surgery + chemo | 16% | (33) | 23% | (23) | 27% | (44) | 10% | (15) | 19% | (115) | ||
| Surgery + radiation | 27% | (55) | 24% | (24) | 23% | (37) | 32% | (47) | 27% | (163) | ||
| Surgery + chemo + radiation | 26% | (53) | 40% | (40) | 38% | (62) | 28% | (41) | 32% | (196) | ||
| Antidepressant Use | 0.41 | |||||||||||
| No | 77% | (155) | 70% | (70) | 71% | (115) | 76% | (113) | 74% | (453) | ||
| Yes | 23% | (46) | 30% | (30) | 29% | (47) | 24% | (36) | 26% | (159) | ||
| Missing | -- | (1) | -- | (0) | -- | (0) | -- | (0) | -- | (1) | ||
* Missing for 1 participant in Study 4 sample. ^ Tested after collapsing to 3 levels: White, Black, Other.